Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

GSK1325756

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Abstract Background Excessive neutrophil migration has been correlated with influenza symptom severity. Danirixin (GSK1325756), a… Expand
  • figure 1
  • table 1
  • table 2
  • table 3
  • figure 2
2018
2018
  • N. Gross
  • Chronic obstructive pulmonary diseases
  • 2018
  • Corpus ID: 4707345
From the GlaxoSmithKline trial of danirixin: “The inflammation associated with chronic obstructive pulmonary disease (COPD) is… Expand
2017
2017
Graphical abstract Figure. No caption available. ABSTRACT The natural variability of gastric pH or gastric acid reducing… Expand
  • figure 1
  • table 1
  • figure 2
  • table 2
  • figure 3
2017
2017
Background: Danirixin (DNX) is a competitive, reversible CXCR2 chemokine receptor antagonist. CXCR2 antagonists inhibit… Expand
2015
2015
BackgroundExcessive neutrophil presence and activation is important in a number of acute and chronic inflammatory diseases. The… Expand
  • figure 1
  • figure 2
  • figure 3
  • table 1
  • table 2
2014
2014
Danirixin (GSK1325756) is a small, high-affinity, selective and reversible CXCR2 antagonist in development for treatment of… Expand
  • figure 1
  • table 1
  • table 2
  • table 3
  • figure 2
2013
2013
Characterization of the biliary disposition of GSK1325756, using a non‐invasive bile sampling technique and spectrometric… Expand